Vaxcyte, Inc. PCVX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s investing cash flow?
- Vaxcyte, Inc. (PCVX) reported investing cash flow of -$233.41M in Q1 2026.
- How has Vaxcyte, Inc.'s investing cash flow changed year-over-year?
- Vaxcyte, Inc.'s investing cash flow decreased by 289.3% year-over-year, from $123.32M to -$233.41M.
- What is the long-term trend for Vaxcyte, Inc.'s investing cash flow?
- Over 3 years (2021 to 2025), Vaxcyte, Inc.'s investing cash flow has grown at a 27.2% compound annual growth rate (CAGR), from -$212.39M to $437.35M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.